EGFR and non-small cell lung carcinoma: Recently, a third-generation TKI, osimertinib, improved progression-free survival (PFS), overall survival (OS) and intracerebral efficacy in comparison to first-generation EGFR TKIs gefitinib or erlotinib in advanced-stage EGFR-mutant NSCLC [6,7] (Supplementary Table S1).